Objective: The spectrum of clinical symptom changes during the course of Parkinson disease (PD). Levodopa therapy, while offering remarkable control of classical motor symptoms, causes abnormal involuntary movements as the disease progresses. This levodopa-induced dyskinesia (LID) has been associated with abnormal cortical plasticity. Because slow wave activity (SWA) of nonrapid eye movement (NREM) sleep underlies adjustment of cortical excitability, we sought to elucidate the relationship between this physiological process and LID. Methods: Thirty-six patients at different stages of PD underwent whole-night video polysomnography-high-density electroencephalography (vPSG-hdEEG), preceded by 1 week of actigraphy. To represent the broad spectrum of the disease, patients were divided into 3 groups by disease stage-(1) de novo (n = 9), (2) advanced (n = 13), and (3) dyskinetic (DYS; n = 14)-were compared to an age-matched control group (n = 12). The SWA-NREM content of the vPSGhdEEG was then temporally divided into 10 equal parts, from T1 to T10, and power and source analyses were performed. T2-T3-T4 were considered early sleep and were compared to T7-T8-T9, representing late sleep. Results: We found that all groups, except the DYS group, manifested a clear-cut SWA decrease between early and late sleep.
P
arkinson disease (PD) is a neurodegenerative disorder presenting with a large spectrum of motor and nonmotor symptoms that are susceptible to change through the course of the disease, depending on the stage of disease progression and on pharmacological therapy. 1 L-dopa is a drug with strong and paradoxical effects on the course of PD; it successfully controls motor symptoms for several years and then induces motor fluctuation and abnormal involuntary movements, that is, L-dopa-induced dyskinesia (LID). This longterm drug-related complication causes important functional disability, often requiring complex pharmacological or surgical interventions.
Although LID is thought to be related to changes in neuronal plasticity in the striatal nuclei, 2 cortical changes are less well-known and are an attractive new area of research. 3 Studies involving repeated transcranial magnetic stimulation show abnormal motor cortex plasticity in patients with LID. 4, 5 Furthermore, changes in cortical slow wave activity (SWA) have been observed in animal models of PD with LID. 6 This finding is of particular interest given that SWA during non-rapid eye movement (NREM) sleep is associated with fine adjustment of cortical excitability and plasticity, as postulated by the synaptic homeostasis hypothesis (SHY). [7] [8] [9] According to this hypothesis, daytime learning processes induce synaptic potentiation represented by an increase in synaptic strength. Conversely, during the subsequent sleep, a consolidation of the learning process occurs together with a synaptic depotentiation represented by a downscaling of synaptic strength. [7] [8] [9] Moreover, SWA-NREM sleep seems to act as a regulator of Hebbian plasticity, preventing saturation of the neuronal network by a sleep-related synaptic downscaling process. 10 Although the SHY requires further confirmation, the key role of sleep in brain plasticity is well supported 11, 12 by morphological evidence of sleep-dependent volumetric reduction of synaptic boutons. 7 Furthermore, drug-induced potentiation of SWA with urethane reduced corticocortical and corticostriatal responses in vivo. 13 Additionally, rodents exposed to combined L-dopa treatment and sleep deprivation developed earlier and more severe LID than animals that were not sleep deprived. 6 Because sleep disturbances are often part of the clinical spectrum of PD, even in the very early stages, we investigated the hypothesis that sleep and its effects on brain plasticity may influence the clinical phenotype of PD.
With the intent of translating the results previously obtained in animals 6 to humans, we explored the correlation between objective sleep parameters and clinical features of different subpopulations of PD patients and agematched controls. Using whole-night video polysomnography-high-density EEG (vPSG-hdEEG), we investigated possible locoregional differences in the homeostatic process that could be limited to discrete brain areas.
14 Some of the results presented here have already been published as a conference paper. 15 
Subjects and Methods

Subjects
All procedures were carried out with the appropriate understanding and written consent of the subjects and had previously been approved by the local ethics committee (Cantonal Ethical Commission, reference number CE2562). This study was registered at ClinicalTrial.gov (reference number NCT02200887). Thirty-six subjects with PD, according to the UK PD Society Brain Bank criteria, 16 were recruited for this study.
Patients were divided into 3 groups, as previously described 17 : (1) de novo (DNV; n = 9), comprising patients with a recent diagnosis, naive to dopaminergic therapy other than rasagiline; (2) advanced (ADV; n = 13), comprising patients not showing LID with their habitual therapy but demonstrating the end-ofdose or wearing-off phenomenon; and (3) dyskinetic (DYS; n = 14), comprising advanced patients experiencing motor fluctuations, showing LID, as confirmed by the enrolling physician.
In agreement with the diagnosis of PD, all DNV patients showed the typical clinical phenotype (eg, asymmetrical parkinsonian syndrome, absence of atypical neurological findings) and normal cerebral magnetic resonance imaging, although an asymmetric dopaminergic deficit with [123I]-FPCIT (DaTscan, GE Healthcare, Chicago, IL) was observed in 3 of 9 patients. Exclusion criteria were evidence for cognitive impairment, as defined by a Mini-Mental State Examination ≤ 24, and age ≥ 75 years. Demographics and clinical characteristics of all patients are shown in Table 1 . An age-matched control group, recruited from accompanying family members, nonclinical hospital staff, and volunteers, was also subjected to the same protocol (CTL; n = 12).
Six of 9 ADV and 10 of 11 DYS patients were administered a combination of L-dopa and dopamine agonist treatment. The L-dopa equivalent daily dose (LEDD) was calculated (Fig 1A) . One DYS patient was excluded because she developed atypical clinical signs suggestive of multiple system atrophy with late onset cardiovascular autonomic failure, urinary voiding disorder, and pyramidal signs, as previously described. 19 
Study Design
At the screening visit (see Fig 1A) , mood and sleep complaints were investigated by means of the modified Beck depression scale, Epworth sleepiness scale, and Pittsburgh sleep quality index. All patients were assessed using the first 3 parts of the Movement Disorder Society-sponsored revision of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) 20 and Hoehn and Yahr (H&Y) staging. 21 In addition, ADV and DYS patients
were assessed using the fourth part of the MDS-UPDRS, and DYS patients were also evaluated with the Abnormal Involuntary Movement Scale (AIMS). 22 After the screening visit, participants FIGURE 1: Design of the study and segments of non-rapid eye movement (NREM) that were subjected to analysis. (A) Schematic flow chart of the study and number of subjects enrolled and tests and/or examinations performed. After the screening visit, participants began the 1-week actigraphy study. Subsequently, the first sleep laboratory habituation night coincided with the last actigraphic day; on the following day, whole-night video polysomnography-high-density electroencephalographic (hd-PSG) recording was performed, and the recordings were assessed and scored. Participants with sleep-related breathing disorders at sleep assessment were excluded from further analysis. Three additional patients were excluded from the slow wave activity (SWA) analysis for misdiagnosis (suspected Lewy body dementia and multiple system atrophy) or for technical reasons.
(B) Whole-night NREM sleep was extracted, epochs containing arousals were excluded, and the remainder was subdivided into 10 equal segments. The 2nd, 3rd, and 4th segments and the 7th, 8th, and 9th segments were selected, as early and late sleep, respectively, and were analyzed further. ADV = advanced; DNV = de novo; DYS = dyskinetic.
underwent a 1-week actigraphic recording (see Fig 1A) . Then, participants arrived at the sleep center at 9:00 PM to prepare for the first habituation night in the sleep laboratory, which coincided with the last day of actigraphic recording. The following night, all patients underwent vPSG-hdEEG recording. The habituation night was included to reduce the "first-night effect" commonly associated with alterations in sleep architecture on the first night of sleep investigation, in comparison to subsequent nights. 23 All patients were followed in our outpatient service for a period of at least 6 months.
Patients were asked to adhere to regular sleep-wake schedules during the study. Antiparkinsonian medication was kept stable throughout the study. All ADV and DYS patients received L-dopa treatment and other antiparkinsonian medications at a stable and optimized dose, as determined by the enrolling neurologists (S.G. and C.S.) for at least 4 weeks before the screening visit.
Based on sleep recordings, both patients and healthy volunteers were assessed for the presence of sleep-related breathing disorders (SRBDs). Because SRBDs are known to disrupt normal sleep architecture and to reduce NREM sleep duration, 24 5 CTL individuals, 3 ADV patients, 1 DYS patient, and 1 DNV patient were excluded from further analysis because of an apneahypopnea index > 5 (see Fig 1A) . For technical reasons, vPSG-hdEEG recording failed in 1 DNV and 1 ADV patient (see Fig 1A) .
Therefore, 7 of 12 CTL individuals, 7 of 9 DNV patients, 9 of 13 ADV patients, and 11 of 14 DYS patients were included in the final sleep analysis. In addition, in 2 DNV patients and in 1 DYS patient, the vPSG-hdEEG recording was corrupted by artifacts (see Fig 1A) and excluded from the SWA analysis. Moreover, 1 DNV, 1 ADV, and 1 DYS patient did not undergo actigraphic monitoring due to technical failure.
Data Analysis
Actigraphy. Wrist actigraphy has been established as a valid and reliable method for assessing the sleep-wake cycle. 25 A wristwatchlike device (Respironics Actiwatch 2;
Philips, Best, the Netherlands) was attached to the subject's nondominant wrist, and data were recorded continuously using 30-second sampling epochs. Actigraphy sleep data were scored by a validated algorithm included in the commercial software to obtain the estimated total sleep time (eTST), estimated time in bed, estimated sleep efficiency (eSE), and estimated sleep latency (eSL).
Whole-Night vPSG-hdEEG Recording. Nocturnal vPSGhdEEG was performed in a standard sound-attenuated sleep laboratory room. Subjects were not allowed to drink caffeinated beverages 6 hours before the beginning of PSG and were allowed to sleep until their spontaneous awakening in the morning. EEG Analysis. EEG data were sampled at 250Hz. Recordings were offline bandpass finite impulse response filtered (0.5-40Hz). NREM sleep data were extracted, epochs containing arousals were excluded, and the remaining data were subdivided into 10 equal segments. We measured the percentage of N3 in each segment and selected the second segment (T2) as the first segment of early sleep to consider to observe a constant decline of SWS content because it contained the greater amount of N3 in each group of subjects or when pooled together. Sleep fragmentation during the falling asleep phase might be the reason for the delay in N3 peak expression. Therefore, the 2nd, 3rd, and 4th segments and the 7th, 8th, and 9th segments were designated as early and late sleep, respectively, and analyzed further (see Fig  1B) using EEGLAB 26 and custom-made MATLAB codes.
The recordings were visually reviewed to exclude artifacts (total time excluded: 3.9%). Bad channels were rejected and replaced using spherical interpolation. The fast Fourier transform was separately calculated for the low (1.5-2.0Hz) and high (2.0-4.0Hz) δ frequency band, re-referenced to the average, downsampled (to 128Hz) 6-second EEG epochs with a 4-second overlap, and tapered with a Hamming window. Individual absolute band power was normalized to the total power. The SWA topographical distribution was obtained. A source analysis was performed for each frequency band to obtain a 3-dimensional cortical distribution of the electric neuronal generators, using standardized lowresolution electromagnetic tomography (sLORETA). 27 The inverse solution was computed within a 3-shell spherical head model, including the scalp, skull, and brain. The 3-layer head model was coregistered to the Talairach human brain atlas. 28 The gray matter compartment was subdivided into 6,340 voxels, with a spatial resolution of 5mm.
Statistical Analysis. Data were first examined for normal distribution using the Shapiro-Wilk test. Parametric data were assessed by 1-way analysis of variance (ANOVA), and in case of significance, differences between pairs of groups were assessed by means of Tukey post hoc tests.
When not normally distributed, the Kruskal-Wallis test followed by a post hoc Mann-Whitney U test was used.
Comparisons were considered statistically significant at a level of p < 0.05. Correlation analyses were performed by means of the nonparametric Spearman test. All tests were performed using IBM Statistics version 20 (IBM, Armonk, NY). Differences in SWA in scalp topography among and between groups were investigated by means of a nonparametric method, based on permutation, 29 with false discovery rate (FDR) correction for multiple comparisons, where a common corrected threshold, identified as the last significant threshold, obtained using the Holms correction, was applied to all p values. The same comparison was also performed on data from a reduced montage corresponding to the frontocentral areas. Differences at the source level were investigated using sLORETA with a statistical nonparametric voxelwise comparison within the CTL, DNV, ADV, and DYS groups for each frequency band. The level of significance was set at p < 0.05.
All the results in the text, tables, and figures are presented as the mean ± standard error of the mean.
Results
Demographics of Control Subjects and PD Patients
Demographic data are detailed in Table 1 .
The mean H&Y stage score was significantly lower for DNV than for ADV and DYS patients (Kruskal-Wallis, χ The motor experiences of daily living (MDS-UPDRS II) showed a significant difference among the 3 patient groups (DNV < DYS: Kruskal-Wallis, χ 2 2 = 6.032, p = 0.049; post hoc: U = 12.00, Z = −2.12, p = 0.34). Regarding the motor assessment (MDS-UPDRS III) in the "on" state, no significant difference was observed among the patient groups.
Subjective Measures of Depression and Sleep Quality All measurements are presented in Table 2 . There was no difference among the 4 groups.
Descriptive PSG Data All descriptive sleep measures are presented in Table 3 . There was no difference among the 4 groups.
RBD and/or REM without atonia were found in 6 of 27 patients (22.2%): 1 DNV (14.2%), 3 ADV (33.3%), and 2 DYS (18.1%) patients.
Correlation between Sleep Measures and Clinical Data
Among the examined PSG and clinical data, we found that TST, SE, and SWS showed significant correlations with disease duration and LEDD (Figs 2 and 3) .
In the patients as a whole (n = 27), disease duration was negatively correlated with TST (Spearman test, r s = −0.527, p = 0.005; see Fig 2A) , but no such correlation was found when examining each group separately (DNV: n = 7, Spearman test, r s = −0.250, p = 0.589; ADV: n = 9, r s = −0.517, p = 0.154; DYS: n = 11, r s = −0.241, p = 0.474; see Fig 2A) .
Similarly, in the patients as a whole (n = 27), there was a negative correlation between disease duration and SE (Spearman test, r s = −0.659, p < 0.001; see Fig 2B) . When considering subgroups of patients, this correlation was maintained only in DYS patients (n = 11, Spearman test, r s = −0.664, p = 0.026), whereas no correlation between disease duration and SE was found in DNV (n = 7, Spearman test, r s = −0.143, p = 0.760) or ADV patients (n = 9, Spearman test, r s = −0.333, p = 0.381; see Fig 2B) . No significant correlation between disease duration and SWS was found in the whole patient group (n = 27, Spearman test, r s = 0.043, p = 0.823; see Fig 2C) . However, when examining the 3 groups separately, we found that both DNV and ADV groups showed a clear positive correlation (DNV: n = 7, Spearman test, r s = 0.786, p = 0.036; ADV: n = 9; r s = 0.783, p = 0.013), whereas the DYS group demonstrated a significant negative correlation between disease duration and SWS (n = 11, Spearman test, r s = −0.761, p = 0.007).
A negative correlation between TST and LEDD was observed in patients with motor fluctuations (ADV and DYS groups: n = 20, Spearman test, r s = −0.475, p = 0.026; Fig 3) . In these patients, LEDD was negatively correlated with SE (ADV and DYS: n = 20, Spearman test, r s = −0.495, p = 0.026). When evaluating the patient groups individually, this negative correlation was still significant in the DYS group (n = 11, Spearman test, r s = −0.633, p = 0.036) but not in the ADV group (n = 9, Spearman test, r s = 0.000, p = 1.000).
Moreover, LEDD was negatively correlated with SWS only in the DYS group (n = 11, Spearman test, r s = −0.682, p = 0.021), whereas no SWS-LEDD correlation was observed in the ADV (n = 9, Spearman test, r s = 0.077, p = 0.845) and combined ADV and DYS groups (n = 20, Spearman test, r s = −0.302, p = 0.195; see Fig 3C) .
Descriptive Actigraphy Data
All the descriptive actigraphic measures are presented in Table 4 . All the measures were similar in all 4 groups (CTL, DNV, ADV, DYS).
Dyskinesia and Motor Fluctuations Correlate Inversely with eTST
We found a negative correlation between eTST and AIMS (DYS: n = 9, Spearman test, r s = −0.733, p = 0.035) and between eTST and MDS-UPDRS IV (DYS: n = 9, Spearman test, r s = −0.817, p = 0.007; Fig 4A) .
We did not observe any correlation of the AIMS and MDS-UPDRS IV scores with eSE (DYS: n = 9, Spearman test, r s = −0.536, p = 0.137 and r s = −0.221, p = 0.567, respectively; see Fig 4B) .
Changes in SWA during Early and Late Sleep
In early sleep, control subjects showed a significantly greater amount of SWA, diffused over the whole scalp, compared to PD patients (p < 0.01, FDR adjusted), as a whole group and separately. Moreover, delta power was greater in DNV compared to the other patient groups (p < 0.01, FDR adjusted) and in ADV compared to DYS (p < 0.01, FDR adjusted), with the DYS group having the lowest content of SWA. As expected, the decrease was mainly in the high δ frequency band (2.0-4.0Hz; Fig  5) . 30 When comparing within groups, we found a significant difference between early and late sleep in the CTL (n = 7), DNV (n = 5), and ADV groups (n = 9, p < 0.01, FDR adjusted) but not in the DYS group (n = 10; see Fig 5B) . In late sleep, when contrasting between groups selecting only frontocentral channels, delta power was lower in DNV compared to the other groups (p < 0.01, FDR adjusted) and in ADV compared to DYS (p < 0.01, FDR adjusted), with the DYS group having the greatest content of SWA among PD patients.
The voxelwise comparison (sLORETA) between groups showed a decrease in SWA between early and late sleep, reaching significance only in the CTL group (n = 7, p < 0.01), localized over frontocentral regions (Brodmann  areas 4, 6, 13, 24, and 31; Fig 7) .
Discussion
L-dopa is currently the most effective available treatment for motor symptoms in PD, but its use is complicated by the development of motor fluctuations and LID. These abnormal movements are mild at the beginning but become disabling as the disease progresses, interfering with quality of life and being a source of morbidity. The pathogenesis of LID is largely unknown, but the onset of PD symptoms at an earlier age, 31 disease duration, 32 and higher cumulative dosage of L-dopa 33 are well-known risk factors for LID development. The involvement of age at onset suggests an underlying genetic background for a dysfunction in brain plasticity, as confirmed by several experiments. 34 Sleep has a function in modulating brain plasticity, 11, 12 but its characteristics in relation to the clinical phenotype of PD have not yet been addressed. Herein, we provided evidence of a close relationship between sleep and several clinical features in a population of patients with PD at different stages, afflicted by motor fluctuations with or without LID. We show the correlation of sleep architecture with disease duration and LEDD and of actigraphic data with the severity of dyskinesia. Importantly, we found an overnight physiological decline in SWA in CTL, DNV, and ADV subjects but not in DYS subjects, who showed a persistent level of SWA throughout the night.
PSG studies of PD have shown conflicting results. 35 For instance, some authors have described changes in SE, TST, SL, and sleep stages in PD patients compared to ADV = advanced patients; CTL = control; DNV = de novo patients; DYS = dyskinetic patients; eSE = estimated sleep efficiency; eSL = estimated sleep latency; eTB = estimated time in bed; eTST = estimated total sleep time.
age-matched healthy controls, 36 whereas others have not found significant differences. 37 However, compared to these previous studies, in this study, we examined sleep architecture with respect to the disease stage and with respect to the presence/absence of motor fluctuations and LID. We would suggest that this patient classification allows a more accurate detection of those differences that would otherwise not be clearly defined in a heterogeneous group. For instance, in the whole PD patient cohort, we found that both the TST and SE were negatively correlated with disease duration, as has been already described, and that whereas the correlation between SWS and disease duration was positive in both DNV and ADV patients, it was surprisingly negative in DYS patients. Diederich and colleagues found a negative correlation between SWS and disease duration, but they did not take the presence of motor fluctuations or LID into account. Because the patient sample was older and featured a longer disease duration than our population, it is likely that they investigated mainly advanced PD patients. 38 Although far from conclusive, the positive correlation between SWS and disease duration in both DNV and ADV patients might reflect compensatory mechanisms within the SHY framework aimed at maintaining an appropriate homeostatic process, which could be ineffective in DYS patients. However, the amount of SWS does not directly reflect a more efficient SWA-mediated downscaling process. 14 As mentioned above, the risk of developing dyskinesia or motor fluctuations is closely linked to the L-dopa cumulative dose. 33 Therefore, we extended our correlation analysis to sleep parameters and LEDD. We found an intriguing negative correlation of TST and SE with LEDD in all patients with motor fluctuations (ADV and DYS groups). Notably, SWS was negatively correlated with LEDD only in patients demonstrating LID. The impact of L-dopa therapy on sleep is not well defined and has been the subject of only few studies. L-dopa may have a direct effect on sleep macrostructure or may improve sleep by improving motor nocturnal performance. In a small sample of PD patients, reduced SWS and REM sleep with prolonged SL and wakefulness after sleep onset (WASO) was observed following the initiation of L-dopa treatment. 39 However, some studies 40 conducted in larger populations of patients did not detect significant changes in SWS and REM sleep, although both SL and WASO were reduced after L-dopa treatment. Similar to our findings, a case-control PSG study revealed reduced TST associated with increased LEDD, 36 although motor fluctuations and LID were not assessed. Although association does not imply causality, the notion of cumulative LEDD as a risk factor for LID suggests that L-dopa use, especially in a day-night pulsatile manner, could be the cause of reduced TST, subsequently enhancing LID. Our 1-week actigraphy data demonstrated a clear negative correlation between eTST and the severity of dyskinesia. Poor nighttime sleep has been positively associated with LID in a recent study with a large cohort of patients. 41 Along these lines, sleep deprivation has been shown to enhance LID in a rodent model 6 and in PD patients. 42 Conversely, subjective clinical amelioration after sleep is frequently mentioned by patients, mainly in those with long disease duration and motor fluctuations.
43,44
The third main finding of our study concerns SWA. Notably, all groups except the DYS group manifested a clear-cut physiological decrease in SWA between early and late sleep. The degree of overnight SWA reduction was notable in CTL individuals, in whom we also found early-late sleep differences in the source reconstruction analysis. The early-late difference was still significant in both the DNV and ADV groups.
The lack of a significant difference between earlylate SWA in DYS patients could be due either to impaired downscaling or to a lower buildup in these patients. DYS patients start from a lower early SWA level compared to the ADV and DNV subjects. However, the observed SWA reduction in early sleep could be a consequence of a chronic deficit of synaptic downscaling during the night in dyskinetic patients. 41 In these respects, chronic sleep deprivation has been associated with an impairment of synaptic potentiation. 45 We are inclined to believe that our results support a disruption of homeostatic process per se. DNV patients have late sleep SWA content lower than ADV and DYS patients, and, even more important to our argument against a flooring effect, lower than CTL participants. Moreover, DYS patients showed a greater amount of SWA in late sleep compared to the other groups. Therefore, if our results were due to an overall SWA impairment and to a floor effect rather than to a disrupted homeostatic process, we would not have expected to We found a significant difference between early and late sleep in CTL (n = 7), DNV (n = 5), and ADV individuals (n = 9, p < 0.01) but not in DYS patients (n = 10), which remained significant after correction for multiple comparisons. (C) Plots of the mean power of high-density (HD; empty dots) or low-density electroencephalography (LD; green dots) in each group of subjects during early and late sleep (CTL, DNV, ADV, and DYS). Lines are the mean of all HD (black) or LD (green) channels. *All groups except the DYS group showed a difference between early and late sleep.
observe the lowest level of early sleep SWA in DYS together with the highest level of late sleep SWA in these patients, but rather a similar content of SWA in late sleep among the groups.
Because dyskinesia is a motor phenomenon, the same analysis performed selecting only the frontal channels heightened the difference between DYS and ADV, and the alteration of homeostatic processes is also confirmed by the results obtained using a frontal low-density EEG channel montage.
The SWA analysis allowed the recognition of differences between CTL individuals and PD patients as well as between advanced patients with or without LID. None of the participants had cognitive impairment, which is usually related to the presence of cortical pathology. 46 Therefore, our results suggest that cortical SWA changes may be associated with the development of LID rather than with a structural pathology. L-dopa-treated dyskinetic rats manifest aberrant corticostriatal synaptic plasticity that impaired the ability of the striatum to discriminate between relevant and irrelevant cortical inputs. 2 From the SHY prospective, the homeostatic changes of net synaptic strength across the sleep-wake cycle define the threshold for associative plasticity; therefore, a reduction of sleep-related synaptic downscaling can hide an abnormal saturation of the corticostriatal network. Certainly, our findings related to cortical plasticity do not exclude an impaired top-down corticostriatal input, which induced pathological plasticity in the striatum, 47 or even that an intrinsic trait in cortical plasticity may predispose a subgroup of patients to LID. Supporting this view, normal motor skill learning and synaptic plasticity require normal dopaminergic input within the primary motor cortex. 13 Dopamine projections to the cortex arise mainly from the ventral tegmental area (VTA), 48 which is involved later in the course of the disease. 49 The timing of the neurodegenerative process that is reflected by the dopamine content in the cortex might underlie the impaired plasticity and the subsequent development of LID. 4, 5 Of note, several lines of evidence have linked LID with impulse-control disorders, which are notoriously associated with VTA dysfunction. 50 In conclusion, these results support our preclinical findings of a clear association between sleep and LID at the electrophysiological, behavioral, and biochemical levels.
Although our findings do not imply a causative role for the lack of SWA reduction in the emergence of LID, in light of the SHY framework, they do suggest an association between sleep and some clinical phenotypes of PD and suggest a relationship between sleep disruption and LID. Additional studies are warranted to establish a causative relationship between an abnormal sleep-related downscaling process and LID development. The small size of our sample, although homogenous and well characterized, represented a limitation of our study, and a larger confirmatory study is needed to support this theory, which will pave the way for pioneering SWA-enhancing therapies in PD.
